Istari Oncology announces dosing of first subject in melanoma trial,

Istari Oncology has announced the dosing of the first subject in the LUMINOS-102 Phase II clinical trial of its viral immunotherapy, PVSRIPO, …, Istari Oncology has announced the dosing of the first subject in the LUMINOS-102 Phase II clinical trial of its viral immunotherapy, PVSRIPO, …, Read More

Scroll to Top